Work

Abstract PO1-20-06: Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 +/- pertuzumab in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan

Year: 2024

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs23-po1-20-06

Authors: Mark Pegram, Carmen Calfa, Chris Chen, Alfonso Cortes Salgado, Arielle Heeke, Irene Kang, Barbara Pistilli, Paula Pohlmann, Hope Rugo, Cristina Saura, Cecile Vicier, Cecelia I. Pearson, Coya Tapia, Ming Yin, Tai Yu, Michael N. Alonso, Edith A. Perez, Joshua Drago

Institutions: Stanford Medicine, Stanford University, University of Miami, Hospital Universitario Ramón y Cajal, City of Hope, Institut Gustave Roussy, The University of Texas MD Anderson Cancer Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Institut Paoli-Calmettes, Memorial Sloan Kettering Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4396591121

Cites:

Cited by:

Related to: 10